← Back to Home

Generating CAR-T Cells Directly in the Body: Legend Biotech’s Dual-Target Therapy Cleared for U.S. Trial

LB2501 aims to move T-cell engineering into patients’ bodies and use dual recognition of CD19 and CD20 to reduce the chances of cancer cells escaping detection. U.S. FDA clearance for clinical testing moves this approach forward, but whether the treatment can work safely and durably remains to be verified.

By SURL BioNews

If cancer-fighting T cells could be generated directly inside patients’ bodies, the way cell therapies are manufactured and delivered could change. Legend Biotech announced on October 15 that the U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application for its investigational therapy LB2501, paving the way for a planned U.S. Phase 1/2 trial.

The trial will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. RTTNews also confirmed the development in a report the same day, emphasizing that LB2501 remains investigational; IND clearance allows clinical testing to proceed, but is neither marketing approval nor an indication that safety and efficacy have been established.

At the core of LB2501 is the delivery, through a single infusion, of the genetic instructions needed to engineer T cells inside the body. According to the company, it uses the TaVec platform and an engineered, replication-incompetent lentiviral vector designed to selectively deliver these instructions into T cells, causing them to express a chimeric antigen receptor (CAR) that recognizes CD19 and CD20, thereby generating CAR-T cells.

The dual-target design seeks to address “antigen escape,” in which cancer cells may lose or reduce expression of a particular antigen to evade recognition. Recognizing both CD19 and CD20 is intended to provide additional routes for recognition; however, this remains a design rationale and does not establish that LB2501 can prevent relapse or overcome treatment resistance.

Background

There are different approaches to improving CAR-T: some studies modify genes and functions within T cells to help them reach tumors and sustain their activity, while generating CAR-T cells inside the body shifts the focus to how the cells are manufactured. Compared with the process of first collecting cells, engineering them outside the body, and then reinfusing them, LB2501 aims to reduce the steps involved in personalized cell manufacturing. Whether a simpler process can translate into broader access to treatment will still need to be determined through clinical experience and subsequent supply experience.

This therapy is not entering human studies for the first time. The company has already conducted a Phase 1 trial in China and released early data from 12 patients in June this year: all 6 patients in the higher-dose group had an objective response, including 5 who achieved a complete response; however, the total number of patients with an objective response across the two dose groups was 6. These small-sample, open-label results provide a basis for further research but are not yet sufficient to assess the consistency and durability of efficacy.

For the forthcoming U.S. study, the key questions extend beyond whether tumors shrink to include how CAR-T cells generated inside the body expand, how long they persist, and whether short-term or delayed adverse reactions occur. A single infusion describes the method of administration; it does not mean that one treatment can provide long-term disease control. This regulatory development creates an opportunity to examine these questions in a new clinical trial.

References

  1. Legend Biotech / GlobeNewswire
  2. RTTNews